Abera Bioscience AB
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
ABERA | SPGR
Overview
Corporate Details
- ISIN(s):
- SE0015245097
- LEI:
- 549300IO3Q8IE2FDUS29
- Country:
- Sweden
- Address:
- BOX 1747, 751 47 Uppsala
- Website:
- https://aberabio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Abera Bioscience AB is a vaccine development company focused on creating next-generation mucosal vaccines. The company utilizes its proprietary vaccine delivery platform, BERA, which is based on decorating Outer Membrane Vesicles (OMVs) with multiple antigens to stimulate a strong and broad immune response. Abera's pipeline includes vaccine candidates suitable for mucosal administration, such as nasal sprays. Its lead candidate is a universal pneumococcal vaccine preparing for clinical trials. The company also develops vaccine technologies for pandemic preparedness, leveraging over 30 years of experience in microbiological research to advance its innovative vaccine programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Abera Bioscience AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Abera Bioscience AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Abera Bioscience AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
